Company Description
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally.
The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.
Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications.
The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system.
The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders.
Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system.
It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 2011 |
| IPO Date | Feb 11, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 970 |
| CEO | Robert Claypoole |
Contact Details
Address: 4721 Emperor Boulevard, Suite 100 Durham, North Carolina 27703 United States | |
| Phone | (919) 474-6700 |
| Website | bioventus.com |
Stock Details
| Ticker Symbol | BVS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.00 |
| CIK Code | 0001665988 |
| CUSIP Number | 09075A108 |
| ISIN Number | US09075A1088 |
| Employer ID | 81-0980861 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Mark L. Singleton | Senior Vice President and Chief Financial Officer |
| Robert Claypoole | President, Chief Executive Officer and Director |
| Mike Crowe B.S., M.B.A. | Senior Vice President of Operations |
| David Crawford | Vice President of Investor Relations and Treasurer |
| Anthony D'Adamio | Senior Vice President, General Counsel and Corporate Secretary |
| Katrina J. Church J.D. | Senior Vice President and Chief Compliance Officer |
| Helen Leupold | Senior Vice President and Chief Human Resources Officer |
| Larry Chen | Managing Director of China and Asia Pacific |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | 144 | Filing |
| Apr 11, 2024 | 144 | Filing |
| Apr 11, 2024 | 144 | Filing |
| Apr 10, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 27, 2024 | 144 | Filing |
| Mar 25, 2024 | 144 | Filing |
| Mar 20, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 12, 2024 | 10-K | Annual Report |
| Mar 12, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |